0001629137 false 0001629137 2020-06-17 2020-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Washington, D.C. 20549



Form 8-K




Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 17, 2020


Global Blood Therapeutics, Inc.
(Exact name of registrant as specified in its charter)


Delaware 001-37539 27-4825712
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)


181 Oyster Point Blvd.

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)


(650) 741-7700

(Registrant's telephone number, including area code)


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share GBT The NASDAQ Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.07 Submission of Matters to a Vote of Security Holders.


The proposals set forth below were submitted to the stockholders at the 2020 Annual Meeting of Stockholders, or Annual Meeting, of Global Blood Therapeutics, Inc., or Company, held on June 17, 2020, with each such proposal described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2020, or Proxy Statement.


The number of shares of common stock entitled to vote at the Annual Meeting was 60,915,556. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 49,911,876. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.


Proposal 1 – Election of Directors


The Company’s stockholders elected the Class II director nominees below to the Company’s Board of Directors to hold office until the 2023 Annual Meeting of Stockholders or until their successors are duly elected and qualified.


Director Nominee Votes For Votes Withheld
Willie L. Brown, Jr. 35,025,579 9,883,586
Philip A. Pizzo, M.D. 35,335,994 9,573,171
Wendy Yarno 35,294,219 9,614,946


There were 5,002,711 broker non-votes regarding this proposal.


Proposal 2 – Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers as Disclosed in the Proxy Statement


The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.


Votes For Votes Against Abstentions
34,679,603 10,066,380 163,182


There were 5,002,711 broker non-votes regarding this proposal.


Proposal 3 – Ratification of Appointment of Independent Registered Accounting Firm


The Company’s stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.


Votes For Votes Against Abstentions
49,805,133 70,394 36,349


There were no broker non-votes regarding this proposal.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Global Blood Therapeutics, Inc.
Date: June 19, 2020 By:  /s/ Jeffrey Farrow
    Jeffrey Farrow
    Chief Financial Officer
(Principal Financial Officer)